Last reviewed · How we verify
Granisetron Transdermal Patch
At a glance
| Generic name | Granisetron Transdermal Patch |
|---|---|
| Also known as | Granisetron Transdermal System, Sancuso, sancuso |
| Sponsor | Gynecologic Oncology Group |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron (PHASE4)
- Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years (PHASE1)
- Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years (PHASE1)
- An Investigation on the Effect of Age and BMI on the Pharmacokinetics of Transdermal Granisetron (PHASE1)
- Effect of External Heat on a Transdermal Granisetron Patch in Pharmacokinetics (PK) of Healthy Subjects (PHASE1)
- Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS) (PHASE1)
- To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV) (PHASE3)
- Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Granisetron Transdermal Patch CI brief — competitive landscape report
- Granisetron Transdermal Patch updates RSS · CI watch RSS
- Gynecologic Oncology Group portfolio CI